Conference Coverage

DECLARE-TIMI58 shows improved kidney function with dapagliflozin

Publish date: July 22, 2019

 

REPORTING FROM ADA 2019

Pages

Recommended Reading

Do black patients with type 2 diabetes gain cardiac benefit from the SGLT2 and GLP-1 drugs?
MDedge Cardiology
The costs and benefits of SGLT2 inhibitors & GLP-1 RAs
MDedge Cardiology
CAROLINA findings reaffirm linagliptin’s safety, free glimepiride of CV-risk stigma
MDedge Cardiology
New findings cast more doubt on ‘fat-but-fit’ theory
MDedge Cardiology
Microvascular disease: An independent and exacerbating risk factor for amputation
MDedge Cardiology
Using Obamacare authority, Trump aims to shift dialysis care to patients’ homes
MDedge Cardiology
BMI screening trigger for type 2 diabetes is unreliable for at-risk black, Hispanic adults
MDedge Cardiology
CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes
MDedge Cardiology
FDA declines dapagliflozin indication as adjunct for type 1 diabetes
MDedge Cardiology
Plant-based foods could keep type 2 diabetes at bay
MDedge Cardiology